Fig. 3From: Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancerChemical structures of KRASG12C covalent inhibitors with their initial publication date. AMG 510 has received accelerated approval from the U.S. FDA for the treatment of patients with NSCLC in May 2021. MRTX849 has been granted Breakthrough Therapy Designation by FDA in June 2021Back to article page